When the equities in your portfolio plummet, you may find yourself asking: What are these stocks really worth? They’ve fallen ten or twenty percent – what’s to keep them from declining even further? Well here’s one thing that can anchor a portfolio: Sizeable dividend payments.
BlueLinx insiders bought after their company's stock price was cut in half after a surprise revenue decline. On Nov. 5, BXC closed at $31. Then came an earnings report showing a significant revenue decline. On Thursday morning BlueLinx (BXC) traded as low as $13.47...
In the investing world, those with superior information usually make the most money. And possibly no group has better information on public companies – and profitably acts on it – than corporate insiders at small-cap biotech and medical technology companies.
In May of 2015, Nelson Obus’s lawyer opened his client’s trial by saying that either the hedge fund manager is an honest man or "the lamest insider trader in history." Twelve years after he was first charged by the SEC for insider trading, Obus, the manager of New York-based hedge fund Wynnefield Capital Inc., was found not guilty by a jury. Fast forward to January 14, 2019 and Obus just submitted an insider filing to his nemesis the SEC,  disclosing that his fund purchased 20,000 shares of Landec Corp. (LNDC) at $11.33. It’s a trade that investors may want to note – not because of any alleged impropriety, but because the stock being bought may be an attractive opportunity.
Fastly Inc. (FSLY) shares surged nearly 45% from July 24 through Aug 5. -- going from $78 to a high of $117.79. But since then, FSLY has pulled all the way back to $79.25. Tons of volatility, but Fastly's #1 holder -- Abdiel Capital -- hasn't sold...
A.H. Belo (AHC) was the target Wednesday afternoon of a 13D filing by Minerva Advisors LLC. The hedge fund disclosed a 5.1% activist ownership position in the publisher of the Dallas Morning News, and said the company should go private. From the 13D filing:
Last week, three insiders from Maiden Holdings, Ltd. (MHLD) filed Form 4s disclosing the purchase of 380,000 shares at an average price of $0.78 per share. An interesting cluster of buying. But here's what's astonishing -- just seven months earlier the stock traded at $8.75.
A Mellanox (MLNX) insider bought $2.2 million of the Israeli chip designer as fears China will block a proposed merger with Nvidia Corp (NVDA) pushed the price of MLNX well below the buyout price. Stephen Sanghi, a director of Sunnyvale-based Mellanox since February...
Myriad Genetics co-founder Walter Gilbert PhD bought $150K of MYGN on Dec. 13 @ $25.60. Gilbert, who won the Nobel Prize for Chemistry in 1980, has a history of Form 4 filings at Myriad dating back to 2006. However, this is the insider's first open market purchase...
Twenty-two minutes after regular market hours closed on July 2, an Orbimed Advisors Form 4 relating to Corvus Pharmaceuticals Inc (CRVS) was posted on the SEC's website. The hedge fund, a 10%+ holder and insider in CRVS, disclosed that between June 27 and July 1 it...